A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis
| Autor: | Toshitaka Nakamura, Hideaki Mizunuma, Yasuo Ohashi, Yuji Taketani, Toshio Matsumoto, Teruki Sone, Hirotoshi Morii, Akira Itabashi, Yoshiki Nishizawa, Masataka Shiraki, Toshiomi Minamide, Hiroshi Hagino |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Minodronic acid
medicine.medical_specialty Histology Physiology Endocrinology Diabetes and Metabolism medicine.medical_treatment Osteoporosis Urology Dentistry Bone remodeling law.invention chemistry.chemical_compound Lumbar Double-Blind Method Randomized controlled trial Bone Density law medicine Humans Adverse effect Osteoporosis Postmenopausal Aged Alendronate Bone Density Conservation Agents Diphosphonates business.industry Alendronic acid Imidazoles Middle Aged Bisphosphonate medicine.disease Treatment Outcome chemistry Female business medicine.drug |
| Zdroj: | Bone. 44:1078-1084 |
| ISSN: | 8756-3282 |
| DOI: | 10.1016/j.bone.2009.02.016 |
| Popis: | Introduction In a randomized, active-controlled, double-blinded, multicenter study, the efficacy and safety of minodronate were examined and compared to that of alendronate. Methods A total of 270 postmenopausal osteoporotic women ≥ 45 years of age were randomized into the minodronate group ( n = 135) or alendronate group ( n = 135). Each subject received 1 mg minodronate or 5 mg alendronate once a day for 12 months. Results Both treatment groups showed similar changes in BMD after 12 months. After 1 year of treatment, the lumbar spine BMD increased by 5.86% and 6.29% in the minodronate and alendronate groups, respectively, and the total hip BMD increased by 3.47% and 3.27%, respectively. Bone turnover markers were rapidly reduced within 1 month in both treatment groups. Urine DPD was significantly lower in the minodronate group than in the alendronate group at 6 months, and urine NTX was significantly lower in the minodronate group than in the alendronate group at 1 and 9 months. Both completion rates for the 12-month study and the overall incidence of clinical adverse events, including gastrointestinal events, were similar between the two groups. Conclusions The effects on lumbar and hip BMD and the safety profile of minodronate are comparable to those of alendronate. Minodronate is a promising new potent bisphosphonate for the treatment of osteoporosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect